ONDCP Appointment of Senior Executive Service Performance Review Board Members

FR: Office of National Drug Control Policy

Published May 13th, 2025

Detected March 14th, 2026

Summary

The Office of National Drug Control Policy (ONDCP) has published a notice announcing the appointment of four individuals to its Senior Executive Service Performance Review Board. The notice identifies Ms. Michele Marx as Chair, along with Ms. Debbie Seguin, Ms. Shannon Kelly, and Mr. Kemp Chester as members.

View original document View source feed page

What changed

The Office of National Drug Control Policy (ONDCP) has issued a notice formally appointing four individuals to its Senior Executive Service (SES) Performance Review Board. These appointments, including Ms. Michele Marx as Chair, are administrative in nature and pertain to the internal functioning of the ONDCP's executive personnel oversight.

This notice is primarily informational for government agencies and legal professionals involved in federal personnel matters. There are no immediate compliance actions required for regulated entities outside of the ONDCP itself. The appointments are effective upon publication, and no specific compliance deadlines or penalties are associated with this administrative notice.

Source document (simplified)

Notice

Appointment of Members of Senior Executive Service Performance Review Board

A Notice by the Office of National Drug Control Policy on 05/13/2025

PDF
Document Details

- Table of Contents

Public Comments
Regulations.gov Data

- Sharing

Print
Document Statistics
Other Formats
Public Inspection Published Document: 2025-08404 (90 FR 20304) Document Headings ###### Executive Office of the President

Office of National Drug Control Policy

AGENCY:

Office of National Drug Control Policy (ONDCP).

ACTION:

Notice of appointments.

SUMMARY:

The following persons have been appointed to the ONDCP Senior Executive Service Performance Review Board: Ms. Michele Marx (as Chair), Ms. Debbie Seguin, Ms. Shannon Kelly, and Mr. Kemp Chester.

FOR FURTHER INFORMATION CONTACT:

Please direct any questions to Anthony Jones, Acting General Counsel, (202) 881-8862, Office of National Drug Control Policy, Executive Office of the President, Washington, DC 20503.

Authority: 5 U.S.C. 4314(c)(1)

Dated: May 8, 2025.

Anthony Jones,

Acting General Counsel.

[FR Doc. 2025-08404 Filed 5-12-25; 8:45 am]

BILLING CODE 3280-F5-P

Published Document: 2025-08404 (90 FR 20304)